FDA Grants Breakthrough Therapy Designation to First-Line Sunvozertinib for EGFR Exon 20+ NSCLC

The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.

Related Keywords

China ,United States ,Dizal Pharma ,Xiaolin Zhang ,Dizal Pharmaceutical Co ,European Union ,Drug Evaluation ,Dizal Pharmaceutical ,